Adaptive Biotechnologies Corp

Adaptive is headquartered in Seattle, Washington and operates primarily as a U.S.-centric business. The company’s clinical revenue is tied to U.S. ordering physicians and U.S. payors, and management notes that clonoSEQ coverage has expanded to more than 300 million covered lives across Medicare, national private payors, and large regional plans. It also serves international laboratory sites through technology transfers, which adds some non-U.S. exposure but remains secondary to the domestic market. Because reimbursement, regulatory approval, and clinical adoption are central to the model, the U.S. market is the key geography for both revenue and operating strategy. The company’s research and collaboration work can also involve global biopharma partners, but the disclosed business remains concentrated in the United States.

Adaptive faces execution risk in a highly competitive and rapidly changing biotechnology market, where diagnostics, life sciences tools, and drug discovery companies all compete for the same customers and data. Its revenue depends heavily on clonoSEQ adoption, reimbursement coverage, and the timing of biopharma sample receipt and milestone recognition, which can create quarter-to-quarter volatility. The company also disclosed that the Genentech agreement has been terminated and is winding down, creating a material risk to Immune Medicine revenue and partner-related cash flows. Operationally, it relies on laboratory performance, data quality, intellectual property protection, and a limited number of suppliers for equipment and materials. More broadly, regulatory changes, reimbursement pressure, AI-related compliance issues, and slower-than-expected market acceptance could all reduce growth or delay profitability.